Eli Lilly reported head-to-head results showing its investigational triple-agonist retatrutide outperformed Novo Nordisk’s Ozempic in a large diabetes study, reinforcing the competitive pressure building across incretin-based therapies. In the highest retatrutide dose group, A1c fell by 2.2 percentage points over 80 weeks versus a 1.8-point decline with Ozempic, alongside markedly greater weight loss. The findings—reported as an on-treatment analysis and therefore sensitive to discontinuations—add another data anchor to the retatrutide profile as Lilly continues to position the drug for broader metabolic indications. The differential weight effect is likely to matter for payers and clinicians evaluating long-term cardiometabolic risk reduction rather than glucose control alone.